...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Degenerative Neurological and Neuromuscular Disease >Emerging treatment options for spasticity in multiple sclerosis – clinical utility of cannabinoids
【24h】

Emerging treatment options for spasticity in multiple sclerosis – clinical utility of cannabinoids

机译：多发性硬化症痉挛的新兴治疗选择–大麻素的临床应用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract: Multiple sclerosis (MS) is a widespread and common disabling autoimmune disease of the central nervous system. The main disabling symptom is muscle spasticity, which occurs in most patients. Treatment of spasticity with existing drugs is often poor, and there is a need for new and additional treatments. This article reviews the use of cannabinoids for the treatment of symptoms in MS, focusing on the pharmacology of Δ9-tetrahydrocannabinol (Δ9-THC), cannabidiol and analog drugs in various formulations, the rationale for their use, and their efficacy and safety in the treatment of MS. It is concluded that of all currently available formulations, only sublingual spray containing Δ9-THC has a sufficient evidence base to justify its use in treatment of spasticity and patient quality of life, particularly in patients' refractory to current treatments.
机译：摘要：多发性硬化症（MS）是一种广泛且常见的中枢神经系统致残性自身免疫性疾病。主要的禁用症状是肌肉痉挛，多数患者都会出现。用现有药物治疗痉挛通常很差，因此需要新的和额外的治疗方法。本文回顾了大麻素在MS症状治疗中的用途，重点介绍了各种配方中的Δ9-四氢大麻酚（Δ9-THC），大麻二酚和类似药物的药理作用，使用原理以及它们在治疗中的有效性和安全性。 MS的治疗。结论是，在所有当前可用的制剂中，仅含Δ9-THC的舌下喷雾剂具有充分的证据基础，足以证明其可用于治疗痉挛和患者生活质量，尤其是对当前治疗无效的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号